Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In 2013, self-harm cost hospitals in England an estimated £128.6m according to a new study led by the Nuffield Department of Population Health (NDPH) and the Centre for Suicide Research (Department of Psychiatry).

The paper, published in Epidemiology and Psychiatric Sciences, provides the first detailed study of self-harm and associated hospital costs. The authors found that the number of people visiting hospital for self-harm injuries is 60% higher than previously estimated by Public Health England. 

Senior author, Professor Keith Hawton, Director of the Centre for Suicide Research said ‘Suicide affects people of all socioeconomic backgrounds and is the leading cause of death in males aged 10-49 years and females age 10-34 years in England and Wales. Approximately half of individuals who die by suicide have a history of self-harm, and hospital presentation for self-harm often occurs shortly before suicide. This highlights the need for primary and secondary prevention interventions that focus on reducing self-harm presentations and on provision of effective aftercare for those who do self-harm.’ 

The study authors estimated that 228,075 hospital visits in England by 159,857 patients (39% male and 61% female) in 2013 were a result of self-harm. Their definition included intentional self-poisoning and self-injury. They found that 30% of self-harm related hospital visits by men were by those aged between 40 and 49 and that 28% of hospital visits related to self-harm in women were by those aged 19 to 29. The incidence of self-harm was lower in coastal areas, higher inland, and highest in London. 

Read the story on the Nuffield Department of Population Health website

Read the story on the Department of Psychiatry website

Similar stories

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.